Zai Lab's Omacycline is approved and Hisun Pharmaceutical has the right to promote in China soon

Recently, Zai Lab Class 1 new drugs "ZL-2401 p-toluenesulfonate tablets" and "ZL-2401 p-toluenesulfonate tablets for injection" (relevant acceptance numbers are CXHS2000002 and CXHS2000003 respectively) have entered the administrative approval stage.

ZL-2401 p-toluenesulfonate (Omadacycline, omacycline tosylate) is a new type of 9-aminomethylcycline drug, after chemical group modification based on the tetracycline antibiotic minocycline The resulting semi-synthetic compound has broad-spectrum antibacterial activity.

Omadacycline was developed by Paratek Pharmaceuticals

The research results of the in vitro antibacterial activity of omacycline by the broth microdilution method by the Institute of Antibiotics of Huashan Hospital showed that: (1) omacycline is the most common pathogen of ABSSSI and CABP, such as Staphylococcus aureus and Streptococcus pyogenes , Streptococcus pneumoniae and Haemophilus influenzae have shown strong in vitro inhibitory activity; (2) Omacycline has a significant antibacterial effect on common drug-resistant strains: Methicillin-resistant Staphylococcus aureus has a significant effect on Austria Marcycline is highly sensitive

In addition to omacycline, Genting Sunyao also introduced a new type of tetracycline antibiotic-eravacycline from Tetraphse Pharmaceuticals